| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/14/2005 | CA2540638A1 Quinoxaline compounds |
| 04/14/2005 | CA2540537A1 New use, pharmaceutical preparations as well as a process for their production |
| 04/14/2005 | CA2540536A1 Salts and polymorphs of a potent antidiabetic compound |
| 04/14/2005 | CA2540507A1 Process for producing 1,4-dihydoxy-2-naphthoic acid |
| 04/14/2005 | CA2540502A1 Use of a compound of formula (i) as an inhibitor of aromatase for therapeutic purposes and compounds of formula (1) thereas |
| 04/14/2005 | CA2540452A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/14/2005 | CA2540343A1 Indole derivatives |
| 04/14/2005 | CA2540289A1 Substituted indole derivatives |
| 04/14/2005 | CA2540062A1 Novel association consisting of an anti-atherothrombotic agent and of a platelet antiaggregating agent |
| 04/14/2005 | CA2540061A1 Phenyl pyrrolidine ether tachykinin receptor antagonists |
| 04/14/2005 | CA2539982A1 Pantoprazole multiparticulate formulations |
| 04/14/2005 | CA2539748A1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 04/14/2005 | CA2539724A1 Process for producing product containing proanthocyanidin in high proportion |
| 04/14/2005 | CA2539438A1 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| 04/14/2005 | CA2539339A1 Compounds and compositions as protein kinase inhibitors |
| 04/14/2005 | CA2539025A1 Composition for treating inflammatory bowel disease |
| 04/14/2005 | CA2539023A1 Triamcinolone acetonide and anecortave acetate formulations for injection |
| 04/14/2005 | CA2539010A1 Gamma-tocopherol treatment for cystic fibrosis |
| 04/14/2005 | CA2537769A1 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium |
| 04/14/2005 | CA2537326A1 C1q related protein |
| 04/14/2005 | CA2536530A1 Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof |
| 04/14/2005 | CA2527617A1 Benzo-(4,5)-thieno-(2,3d)-pyrimidin-4-ones and their use in the treatment or prevention of a steroid hormone dependent disease or disorder |
| 04/14/2005 | CA2515583A1 Hydrolases, nucleic acids encoding them and methods for making and using them |
| 04/14/2005 | CA2470908A1 Therapy for cancer |
| 04/13/2005 | EP1522584A2 Phosphatidylinositol 3-kinase p110 delta catalytic subunit |
| 04/13/2005 | EP1522583A2 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina) |
| 04/13/2005 | EP1522579A2 Hyaluronan synthase gene and uses thereof |
| 04/13/2005 | EP1522543A1 Use Steroid sulphatase inhibitors for the manufacture of a medicament for the treatment of an oestrogen dependent tumour |
| 04/13/2005 | EP1522542A1 Therapeutic or preventive agent for nausea/vomiting |
| 04/13/2005 | EP1522540A1 Azaarene derivatives |
| 04/13/2005 | EP1522539A1 Crystalline composition containing escitalopram |
| 04/13/2005 | EP1522314A1 Remedies for diseases caused by vascular contraction or dilation |
| 04/13/2005 | EP1522313A1 Combination therapy of radiation and valdecoxib for the treatment of neoplasia |
| 04/13/2005 | EP1522310A1 Therapeutic uses of dunaliella powder |
| 04/13/2005 | EP1522305A1 Combinations of sumatriptan with a cyclooxygenase II inhibitor |
| 04/13/2005 | EP1522304A2 Compositions containing avenanthramides from extract of oats |
| 04/13/2005 | EP1522219A1 Antiparasitic formulations |
| 04/13/2005 | EP1521847A2 Marker genes for determining renal toxicity |
| 04/13/2005 | EP1521832A2 Genes |
| 04/13/2005 | EP1521828A2 Production of polyketides |
| 04/13/2005 | EP1521779A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 04/13/2005 | EP1521778A1 O-sulphated bacterial polysaccharides and their use |
| 04/13/2005 | EP1521768A2 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/13/2005 | EP1521765A1 Bafilomycin-like metabolite from a novel micromonospora species |
| 04/13/2005 | EP1521764A2 New compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 04/13/2005 | EP1521763A2 Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use |
| 04/13/2005 | EP1521757A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 04/13/2005 | EP1521756A1 Hetero-cyclicaly substituted imidazotriazines |
| 04/13/2005 | EP1521754A2 Viral inhibitors |
| 04/13/2005 | EP1521752A1 Novel macrocycles for the treatment of cancer |
| 04/13/2005 | EP1521750A1 Novel macrocycles for the treatment of cancer diseases |
| 04/13/2005 | EP1521749A1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES |
| 04/13/2005 | EP1521748A1 Novel anthracene derivatives and the use thereof as a medicament |
| 04/13/2005 | EP1521744A1 Arylsulphonamide derivatives and use thereof as b1 bradykinin receptor antagonists |
| 04/13/2005 | EP1521743A1 Hmg-coa reductase inhibitors |
| 04/13/2005 | EP1521740A2 Probucol derivatives |
| 04/13/2005 | EP1521735A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 04/13/2005 | EP1521733A1 Modulators of the glucocorticoid receptor |
| 04/13/2005 | EP1521599A2 Absorption enhancing agent |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521595A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 04/13/2005 | EP1521590A1 Novel medicament combinations based on magnesium salts and fibrinolytics |
| 04/13/2005 | EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 04/13/2005 | EP1521585A1 Immunostimulation by chemically modified rna |
| 04/13/2005 | EP1521584A1 Purine derivatives as liver x receptor agonists |
| 04/13/2005 | EP1521583A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives |
| 04/13/2005 | EP1521581A1 Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis |
| 04/13/2005 | EP1521580A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 04/13/2005 | EP1521579A1 Novel medicament combinations based on sodium channel blockers and magnesium salts |
| 04/13/2005 | EP1521578A2 A novel use of rapamycin and structural analogues thereof |
| 04/13/2005 | EP1521577A1 Methods of using isothiazole derivatives to treat cancer or inflammation |
| 04/13/2005 | EP1521576A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and pde-iv inhibitors |
| 04/13/2005 | EP1521573A1 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| 04/13/2005 | EP1521572A1 Bioerodible film for ophthalmic drug delivery |
| 04/13/2005 | EP1521571A1 Solid dispersion comprising two different polymer matrixes |
| 04/13/2005 | EP1521570A1 Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition |
| 04/13/2005 | EP1521535A1 Improved bulking agent composition |
| 04/13/2005 | EP1521523A2 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| 04/13/2005 | EP1480736A4 Microcapsules having high carotenoid content |
| 04/13/2005 | EP1476193A4 A weight management system for obese animals |
| 04/13/2005 | EP1474171A4 Weight management system for obese animals |
| 04/13/2005 | EP1465912A4 Novel chimeric tnf ligands |
| 04/13/2005 | EP1458702B1 Luminacin analogs and uses thereof |
| 04/13/2005 | EP1450815A4 Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
| 04/13/2005 | EP1434582B1 Topical composition containing brucine and the use for the treatment of damaged mammalian skin |
| 04/13/2005 | EP1367996A4 Sustained-release suspension of ceftiofur hydrochloride |
| 04/13/2005 | EP1366050B1 Condensed pyrazindione derivatives as pde inhibitors |
| 04/13/2005 | EP1365776B1 Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| 04/13/2005 | EP1347986B1 Crystalline glucosamine sulphate metal salts and processes for preparing the same |
| 04/13/2005 | EP1347787B1 Use of dexpanthenol in contact lens care compositions |
| 04/13/2005 | EP1307185B1 Use of carboanhydrase inhibitors for the prevention of diabetic retinopathy in diabetics |
| 04/13/2005 | EP1306067A4 Method for damaging thermo non-tolerance pathologic structures of a warm-blooded organism |
| 04/13/2005 | EP1303296B1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof |
| 04/13/2005 | EP1294739B1 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity |
| 04/13/2005 | EP1289955B1 Piperidines for use as orexin receptor antagonists |
| 04/13/2005 | EP1268498B1 Cardioprotective phosphonates |
| 04/13/2005 | EP1257270B1 A method for synthesizing leflunomide |
| 04/13/2005 | EP1254104B1 Quaternary ammonium compounds and their use as anti-tussive agent |
| 04/13/2005 | EP1246827B1 New polymorphic forms of olanzapine |